1. Patient Disposition
James A. de Lemos et al. JAMA 2004; 292:

2. Baseline Characteristics
James A. de Lemos et al. JAMA 2004; 292:

3. Blood Chemistry Values
James A. de Lemos et al. JAMA 2004; 292:

4. Estimates of the Rate of the Primary End Point
James A. de Lemos et al. JAMA 2004; 292:

5. Secondary and Tertiary End Points
James A. de Lemos et al. JAMA 2004; 292:

6. Estimates of Hazard Ratio for the Primary End Point Within the First 4 Months After Randomization and Between Months 4 and 24
James A. de Lemos et al. JAMA 2004; 292:

7. Estimates of Hazard Ratio for the Primary End Point in Selected Prespecified Subgroups I
James A. de Lemos et al. JAMA 2004; 292:

8. Estimates of Hazard Ratio for the Primary End Point in Selected Prespecified Subgroups II
James A. de Lemos et al. JAMA 2004; 292:

9. Adverse Events by Time From Enrollment
James A. de Lemos et al. JAMA 2004; 292: